BOSTON--(BUSINESS WIRE)--Aciex Therapeutics, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued a U.S. Patent (No. 8,829,005) covering AC-170 Cetirizine Ophthalmic Compositions and a U.S. Patent (No. 8,765,725) covering AC-155 Fluticasone Propionate Nano-crystalline Compositions. Aciex is a private, US-based ophthalmic development pharmaceutical company with a strong near-term pipeline of therapeutics addressing major segments of the ophthalmic market, including allergy and inflammation.
On July 1, 2014, Nicox S.A. (NYSE Euronext Paris: COX) signed an agreement to acquire Aciex Therapeutics, Inc. For more information, see Nicox press release dated July 2, 2014 available on Nicox’s website.
Help employers find you! Check out all the jobs and post your resume.
